Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infant pertussis vaccine priming study comparing acellular versus whole-cell vaccines
2019-001789-13Phase 3Unknown
- Sponsor
- University of Oxford
- Start
- Nov 2019
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of DTaP-IPV-Hep B-PRP-T vaccine and Unifive in pertussis (2 arms), sponsored by University of Oxford. Primary endpoint: Pertussis Toxin-specific antibody Geometric Mean Concentration at 13 months. Status: unknown.
02
Drugs
DTaP-IPV-Hep B-PRP-T vaccineUnifive
03
Conditions
pertussis
Beyond the preview
Go deeper on 2019-001789-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001789-13.